Who are alpha methyldopa's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): tetracaine HCl and oxymetazoline HCL, dexmedetomidine-esketamine-ropivacaine combination 1, APO-clonidine, Dexmedetomidine 01, Preemptive Dexmedetomidine injection, dexmedetomidine 2.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alpha-methyldopa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

alpha methyldopa — Competitive Intelligence Brief

alpha methyldopa (alpha methyldopa) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Central-acting alpha-2 adrenergic agonist. Area: Cardiovascular.

marketed Central-acting alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

alpha methyldopa (alpha methyldopa) — Radboud University Medical Center. Alpha methyldopa is a prodrug that is converted to alpha-methylnorepinephrine, which acts as a central-acting alpha-2 adrenergic agonist to reduce sympathetic outflow and lower blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
alpha methyldopa TARGET	alpha methyldopa	Radboud University Medical Center	marketed	Central-acting alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
tetracaine HCl and oxymetazoline HCL	tetracaine HCl and oxymetazoline HCL	Louisiana State University Health Sciences Center in New Orleans	marketed	Local anesthetic with vasoconstrictor combination	Voltage-gated sodium channels (tetracaine); alpha-2 adrenergic receptors (oxymetazoline)
dexmedetomidine-esketamine-ropivacaine combination 1	dexmedetomidine-esketamine-ropivacaine combination 1	Peking University First Hospital	marketed	Combination anesthetic/analgesic	Alpha-2 adrenergic receptor, NMDA receptor, voltage-gated sodium channels
APO-clonidine	APO-clonidine	University Health Network, Toronto	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Dexmedetomidine 01	Dexmedetomidine 01	Guangzhou General Hospital of Guangzhou Military Command	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Preemptive Dexmedetomidine injection	Preemptive Dexmedetomidine injection	China International Neuroscience Institution	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
dexmedetomidine 2	dexmedetomidine 2	National Cancer Institute, Egypt	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Central-acting alpha-2 adrenergic agonist class)

Radboud University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). alpha methyldopa — Competitive Intelligence Brief. https://druglandscape.com/ci/alpha-methyldopa. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab